Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg


Tuesday, 18 Jun 2013 11:58pm EDT 

Glenmark Pharmaceuticals Ltd announced that it has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (U.S. FDA) for Riluzole Tablets, 50mg. The Company will commence shipping immediately. Riluzole is indicated for the treatment of amyotrophic lateral sclerosis. 

Company Quote

732.7
-15.5 -2.07%
5:22am EST